Novo Nordisk A/S Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Novo Nordisk A/S (NVO).

Back to Analysis Hub

Give me a comprehensive price target analysis for Novo Nordisk A/S (NVO).

Below is a comprehensive analysis of Novo Nordisk A/S (NVO) as of 2025-10-10, combined with three horizontal price targets plotted on the current chart. The three lines (Low, Median, High) were drawn as requested and extended 30 days into the future.

  • Low Target line: 54.00
  • Median Target line: 66.00
  • High Target line: 78.00

Notes on the lines:

  • Each line is horizontal at the specified price and extended to 2025-11-09 (30 days after today) on the active price chart.
  • Colors used: Low (Dodger Blue), Median (Lime Green), High (Orange).

Executive Summary

  • Novo Nordisk remains a high-quality, cash-generative pharma company with a dominant diabetes and obesity drug franchise, strong margins, and a robust balance sheet. The stock trades at a modest forward multiple with a healthy dividend yield, supported by ongoing demand for GLP-1 mechanisms and chronic-disease franchises.
  • Key near-term setup is constructive but nuanced by EPS volatility across quarterly reporting, revisions dynamics, and macro FX exposure. Technicals show the stock trading above the 50-day moving average, with momentum improving modestly as MACD turns toward a positive region, while RSI remains in the mid-range.
  • Our internal price targets (Low/Median/High) imply an increasingly constructive view over different time horizons, while recognizing potential headwinds. We do not have an official analyst target set for NVO in the provided data, so we base targets on a synthesis of earnings signals, fundamentals, and chart context.

Fundamental Analysis

  • Key Metrics
    • Current Price: 58.68
    • Market Cap: 262.43B
    • Enterprise Value: 345.21B
    • Valuation: Trailing P/E 14.97; Forward P/E 14.42
    • Price to Book: 1.55
    • Return on Equity: 79.2%
    • Return on Assets: 21.8%
    • Gross Margin: 84.26%; Operating Margin: 43.52%; Net Margin: 35.61%
    • Debt to Equity: 59.1%; Total Cash: 18.93B; Total Debt: 99.27B
    • Dividend Yield: 2.9% (five-year avg 1.53%)
    • Beta: 0.33 (low relative volatility versus the market)
  • Financial Health Snapshot
    • The company carries meaningful gross and operating margins with substantial cash generation. However, a sizable debt load exists relative to cash, implying a net debt position. Net debt approximates 80.3B (Total Debt minus Total Cash).
    • The dividend is well-supported by cash flow, with a higher current yield versus the five-year average, suggesting the payout policy remains a meaningful component of total return.
  • Practical takeaway: At a mid-teens forward multiple with robust margin structure and a strong cash position, NVO sits in a relatively defensive, high-quality franchise albeit exposed to currency translation (DKK- vs. USD/EUR) and regulatory/competitive risks.

Earnings Analysis

  • Recent Earnings Summary (selected highlights; all figures in USD unless stated)
    • 2025-06-30: Total Revenue 76.86B; EBITDA 43.60B; EBIT 38.76B; Net Income 26.50B; Diluted EPS 5.96
    • 2025-03-31: Total Revenue 78.09B; EBITDA 46.05B; EBIT 42.22B; Net Income 29.03B; Diluted EPS 6.53
    • 2024-12-31: Total Revenue 85.68B; EBITDA 34.94B; EBIT 34.94B; Net Income 28.23B; Diluted EPS 6.12
    • 2024-09-30: Total Revenue 71.31B; EBITDA 37.36B; EBIT 35.21B; Net Income 27.30B; Diluted EPS 6.12
    • 2024-06-30: Total Revenue 68.06B; EBITDA 35.74B; EBIT 26.89B; Net Income 20.05B; Diluted EPS 4.49
  • EPS Trends
    • 0q (most recent quarter): current 4.3857; 7d ago 4.3857; 30d ago 5.896; 60d ago 5.892; 90d ago 6.3803
    • +1q: current 6.2097; 7d ago 6.2097; 30d ago 6.0363; 60d ago 6.0323; 90d ago 6.8933
    • 0y: current 23.7391; 7d ago 23.7391; 30d ago 24.8504; 60d ago 24.5178; 90d ago 25.9598
    • +1y: current 25.1250; 7d ago 25.1250; 30d ago 25.3737; 60d ago 25.5137; 90d ago 29.7373
    • Interpretation: The 0q EPS is materially lower than the year-ago levels, indicating a softer quarter vs. last year’s peak, but the year-ago base (0y and +1y) shows much higher levels, consistent with a high, lumpy earnings base from the GLP-1 portfolio and other drivers. The +1q figure suggests a rebound versus the most recent quarter, indicating potential sequential improvement.
  • EPS Revisions
    • 0q: Up Last7Days = 0; Up Last30Days = 1; Down Last30Days = 2; Down Last7Days = 2
    • +1q: Up Last7Days = 1; Up Last30Days = 3; Down Last30Days = 0; Down Last7Days = 1
    • 0y: Up Last7Days = 0; Up Last30Days = 0; Down Last30Days = 6; Down Last7Days = 3
    • +1y: Up Last7Days = 0; Up Last30Days = 1; Down Last30Days = 1; Down Last7Days = 1
    • Interpretation: Short-term revision sentiment has shown some upticks but remains modest overall, with more downgrades than upgrades in the 0y window. The +1q data show some improvement in the near term revisions. The revisions data imply continued evaluation by analysts, with a tilt toward caution in the near term but potential uplift as earnings momentum stabilizes.
  • Technical Context
    • 50-day MA shows a rising but still-lagging trend relative to the price, with price currently above the MA (price ≈ 58.68 vs MA ≈ 55.1 as of early Oct 2025 data), supporting a mildly bullish tilt.
    • RSI (14) around the mid- to low-40s in recent readings, signaling room to run if momentum improves.
    • MACD is transitioning toward a positive region (recent MACD near +0.6 to +0.8 with a rising signal), suggesting a potential near-term bullish cross if momentum persists.

Analyst Consensus & Price Targets

  • Official Analyst Targets: None provided in the supplied data (Analyst Price Targets: {}).
  • Coverage: Not specified in the data.
  • Implication: Without a published consensus, investors should rely on internal scenario analysis and the company’s fundamental/technical setup to guide targets and risk assessment.

Price Target Analysis (Short, Mid, Long-Term)

  • Base-case price targets (Low, Median, High) drawn from our internal framework and the latest earnings/dynamics:
    • Low Target: 54.00
    • Median Target: 66.00
    • High Target: 78.00
  • Rationale by horizon:
    • Short-Term (3 months) – Target 66.00 (Median)
      • Justification: Near-term EPS revisions pockets show some improvement in the +1q revisions, and the stock trades above the 50-day moving average with a positive MACD trend. A re-rate toward fair value could occur as quarterly momentum stabilizes and FX headwinds moderate. The 66 target implies roughly 12% upside under a base-case scenario, aligning with a modest earnings contribution and valuation re-rating if the narrative remains favorable.
      • Key drivers: Sequential earnings stabilization, improving revisions in the near term, continued cash generation and disciplined capital allocation, and potential GLP-1 growth upside.
    • Mid-Term (12 months) – Target 78.00
      • Justification: A more constructive view as the GLP-1 era sustains volume growth, obesity/diabetes tailwinds persist, and margins remain resilient. A re-rating to mid-to-high teens forward multiples could occur if earnings momentum remains positive and FX remains constructive. The 78 target implies about 18%+ upside from today.
      • Key drivers: Sustained GLP-1 demand, product mix optimization, robust operating leverage, and ongoing dividend capital return.
    • Long-Term (3+ years) – Target around 82.00+
      • Justification: If Novo continues to expand its addressable markets (diabetes, obesity, and potential new indications or products), with operating margins staying robust and cash flow accelerating, a longer-horizon target in the low- to mid-80s could be plausible. This reflects continuous earnings growth, potential new approvals, and favorable structural tailwinds for chronic-disease therapeutics.
      • Key drivers: Pipeline advancements, new indications, international expansion, potential further efficiency gains, and currency/FX tailwinds stabilizing.

Important: The three lines plotted on the chart reflect the Low/Median/High price targets (54/66/78) and are intended to anchor the analysis. The long-term discussion above considers upside beyond these lines if structural growth drivers materialize.

Technical Analysis – Context and Takeaways

  • Price action: Around 58.7, modestly above 50-day MA (~55.1). The gap suggests a constructive medium-term setup, with room for a test of the 60s if catalysts improve.
  • MACD / RSI: MACD has turned toward positive territory, supporting a potential breakout scenario. RSI around the high 30s to low 40s indicates room for upside before hitting overbought territory.
  • Trend confirmation: If the stock maintains price above the 50-day MA and MACD remains positive, a move into the 60s and beyond could occur, aligning with the Median/High target path.

Key Risks & Opportunities

  • Key Risks
    • Currency exposure (DKK/USD/EUR) impacting reported margins and cash flows.
    • Competitive dynamics and regulatory shifts in diabetes/metabolic space.
    • Earnings volatility in a high-growth GLP-1 era, particularly around new indications, price pressure, or changes in reimbursement.
    • Slower-than-expected pipeline progress or delays in approvals.
  • Key Opportunities
    • Continued growth in GLP-1 therapies and obesity indications could sustain top-line growth and margin resilience.
    • Potential expansion into additional chronic-disease franchises or new indications.
    • Shareholder-friendly capital allocation (dividends, buybacks) supporting total return.

Investment Recommendation

  • Recommendation: Hold to mildly bullish in the near-to-medium term, with a constructive bias if earnings revisions improve and the technical setup maintains bullish momentum.
  • Time Horizon: 12–24 months
  • Expected Return Potential: In-line to mid-teens annualized potential (subject to FX, regulatory, and clinical outcomes). The internal price targets imply roughly 12% upside in 3 months (66), ~18% in 12 months (78), with meaningful longer-term upside if growth accelerates beyond the base case (to the low-80s or higher).

Appendix: Earnings/EPS Reference Points (Why targets matter)

  • EPS Trends (selected):
    • Short-term quarter (0q): ~4.39
    • Next quarter ( +1q): ~6.21
    • 0y trailing: ~23.74
    • 1y forward: ~25.13
  • EPS Revisions (selected):
    • 0q: Slightly negative near-term revision balance (more downgrades in the last 30-60 days)
    • +1q: Some improvement in near-term revisions
    • 0y, +1y: Net downgrades visible in the longer horizon
  • Implication: Near-term revisions paint a cautious view, but the positive momentum in the +1q data and the embedded quality of Novo’s cash flows argue for a constructive stance over the 12–24 month horizon if earnings momentum stabilizes.

Tables: Selected Data Points (condensed for quick reference)

  • Key Fundamentals
    • Metric | Value
    • Current Price | 58.68
    • Market Cap | 262.43B
    • EV | 345.21B
    • Trailing P/E | 14.97
    • Forward P/E | 14.42
    • P/B | 1.55
    • ROE | 79.17%
    • ROA | 21.82%
    • Gross Margin | 84.26%
    • Operating Margin | 43.52%
    • Net Margin | 35.61%
    • Debt/Equity | 59.1%
    • Total Cash | 18.93B
    • Total Debt | 99.27B
    • Dividend Yield | 2.90%
    • 5yr Avg Dividend Yield | 1.53%
    • Beta | 0.33
  • Earnings Snapshot (selected)
    • Period | Total Revenue | EBITDA | EBIT | Net Income | Diluted EPS
    • 2025-06-30 | 76.86B | 43.60B | 38.76B | 26.50B | 5.96
    • 2025-03-31 | 78.09B | 46.05B | 42.22B | 29.03B | 6.53
    • 2024-12-31 | 85.68B | 34.94B | 34.94B | 28.23B | 6.12
    • 2024-09-30 | 71.31B | 37.36B | 35.21B | 27.30B | 6.12
    • 2024-06-30 | 68.06B | 35.74B | 26.89B | 20.05B | 4.49
  • EPS Trends (selected)
    • 0q current: 4.39; 7d Ago: 4.39; 30d Ago: 5.90; 60d Ago: 5.89; 90d Ago: 6.38
    • +1q current: 6.21; 7d Ago: 6.21; 30d Ago: 6.04; 60d Ago: 6.03; 90d Ago: 6.89
    • 0y current: 23.74; 7d Ago: 23.74; 30d Ago: 24.85; 60d Ago: 24.52; 90d Ago: 25.96
    • +1y current: 25.13; 7d Ago: 25.13; 30d Ago: 25.37; 60d Ago: 25.51; 90d Ago: 29.74
  • EPS Revisions (summary)
    • 0q: UpLast7Days=0; UpLast30Days=1; DownLast30Days=2; DownLast7Days=2
    • +1q: UpLast7Days=1; UpLast30Days=3; DownLast30Days=0; DownLast7Days=1
    • 0y: UpLast7Days=0; UpLast30Days=0; DownLast30Days=6; DownLast7Days=3
    • +1y: UpLast7Days=0; UpLast30Days=1; DownLast30Days=1; DownLast7Days=1

If you’d like, I can add an alternative set of price targets (e.g., 50/62/75 or 56/68/82) to test sensitivity, or tailor the targets to a specific scenario (FX headwinds, a major pipeline readout, or a regulatory development).

Chart is loading...